Glioma Stem Cells

[1]  D. Silbergeld,et al.  Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. , 2014, The Journal of clinical investigation.

[2]  I. Germano,et al.  Stem cells and gliomas: past, present, and future , 2014, Journal of Neuro-Oncology.

[3]  A. Vescovi,et al.  Glioma stem cells: turpis omen in nomen? (the evil in the name?) , 2014, Journal of internal medicine.

[4]  R. Bronson,et al.  Inhibition of EGFR Induces a c‐MET‐Driven Stem Cell Population in Glioblastoma , 2014, Stem cells.

[5]  D. Placantonakis,et al.  Brain stem cells as the cell of origin in glioma. , 2014, World journal of stem cells.

[6]  M. K. Cooper,et al.  Cancer stem cells in glioma: challenges and opportunities. , 2013, Translational cancer research.

[7]  M. Toda.  Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas , 2013, ISRN oncology.

[8]  Andrew W Boyd,et al.  EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. , 2013, Cancer cell.

[9]  G. Maira,et al.  The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. , 2012, Cancer cell.

[10]  L. Donovan,et al.  CD133: holy of grail of neuro‐oncology or promiscuous red‐herring? , 2012, Cell proliferation.

[11]  C. Richichi,et al.  Current Strategies for Identification of Glioma Stem Cells: Adequate or Unsatisfactory? , 2012, Journal of oncology.

[12]  L. Parada,et al.  Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells , 2012, Cell.

[13]  Daniel J. Hoeppner,et al.  Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions , 2011, Cell Death and Disease.

[14]  A. Vescovi,et al.  Evidence for label-retaining tumour-initiating cells in human glioblastoma. , 2011, Brain : a journal of neurology.

[15]  Qiulian Wu,et al.  Elevated invasive potential of glioblastoma stem cells. , 2011, Biochemical and biophysical research communications.

[16]  G. Fròsina.  Frontiers in targeting glioma stem cells. , 2011, European journal of cancer.

[17]  Jane E. Visvader,et al.  Cells of origin in cancer , 2011, Nature.

[18]  Mauro Biffoni,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[19]  Zhaokai Wang,et al.  PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells , 2011, Molecular and Cellular Biochemistry.

[20]  M. Weller,et al.  Glioblastoma stem cells , 2011, Cell and Tissue Research.

[21]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[22]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[23]  Michelle J Hickey,et al.  Cellular and vaccine therapeutic approaches for gliomas , 2010, Journal of Translational Medicine.

[24]  P. Brastianos,et al.  Vascular endothelial growth factor inhibitors in malignant gliomas , 2010, Targeted Oncology.

[25]  Qiulian Wu,et al.  Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting , 2010, Protein & Cell.

[26]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[27]  Jian Wang,et al.  Glioma cell populations grouped by different cell type markers drive brain tumor growth. , 2010, Cancer research.

[28]  R. McLendon,et al.  Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.

[29]  P. Malatesta,et al.  Recent Insights into PDGF‐Induced Gliomagenesis , 2010, Brain pathology.

[30]  Serban Nacu,et al.  A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. , 2010, Cancer cell.

[31]  H. Fine,et al.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas , 2010, Cancer.

[32]  R. Spang,et al.  Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. , 2010, Cancer research.

[33]  J. Tonn,et al.  Presence of pluripotent CD133+ cells correlates with malignancy of gliomas , 2010, Molecular and Cellular Neuroscience.

[34]  J. Rich,et al.  Hypoxia inducible factors in cancer stem cells , 2010, British Journal of Cancer.

[35]  G. Alexiou,et al.  The role of the PTEN gene in malignant gliomas. , 2010, Neurologia i neurochirurgia polska.

[36]  A. Argyriou,et al.  An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines , 2010, Investigational New Drugs.

[37]  Jeremy Stinson,et al.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.

[38]  Yunqing Li,et al.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. , 2009, Cancer research.

[39]  E. Raymond.  PDGFR inhibition in brain tumours--oft expectation fails where most it promises. , 2009, European journal of cancer.

[40]  T. Mikkelsen,et al.  The induction of autophagy by γ‐radiation contributes to the radioresistance of glioma stem cells , 2009, International journal of cancer.

[41]  Deric M. Park,et al.  Biology of glioma cancer stem cells , 2009, Molecules and cells.

[42]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[43]  H. Colman,et al.  Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters , 2009, Oncogene.

[44]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[45]  Rakesh K. Jain,et al.  PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment , 2009, PloS one.

[46]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[48]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[49]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[50]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[51]  D. Capper,et al.  Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation , 2009, Acta Neuropathologica.

[52]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  P. Febbo,et al.  Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. , 2009, Cancer cell.

[54]  P. Pandolfi,et al.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. , 2009, Neuro-oncology.

[55]  Brent A Reynolds,et al.  Isolation, expansion, and differentiation of adult Mammalian neural stem and progenitor cells using the neurosphere assay. , 2009, Methods in molecular biology.

[56]  Tao Song,et al.  Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients , 2008, Journal of experimental & clinical cancer research : CR.

[57]  L. Ricci-Vitiani,et al.  Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[58]  R. McLendon,et al.  Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition , 2008, Stem cells.

[59]  D. Koul.  PTEN Signaling pathways in glioblastoma , 2008, Cancer biology & therapy.

[60]  K. Shiota,et al.  Hedgehog signaling is involved in development of the neocortex , 2008, Development.

[61]  R. McLendon,et al.  Targeting cancer stem cells through L1CAM suppresses glioma growth. , 2008, Cancer research.

[62]  B. Kristensen,et al.  CD133 identifies perivascular niches in grade II–IV astrocytomas , 2008, Journal of Neuro-Oncology.

[63]  U. Bogdahn,et al.  CD133 Expression and Cancer Stem Cells Predict Prognosis in High‐grade Oligodendroglial Tumors , 2008, Brain pathology.

[64]  S. Kesari,et al.  Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas , 2008, Nature Clinical Practice Oncology.

[65]  R. McLendon,et al.  Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. , 2008, Neuro-oncology.

[66]  Mark Noble,et al.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system , 2008, Journal of biology.

[67]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[68]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[69]  A. Bergenheim,et al.  Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model , 2008, Journal of Neuro-Oncology.

[70]  P. Lichter,et al.  Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients , 2008, Clinical Cancer Research.

[71]  Susan M. Chang,et al.  Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[72]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[73]  D. Durden,et al.  Mechanisms of Disease: the PI3K–Akt–PTEN signaling node—an intercept point for the control of angiogenesis in brain tumors , 2007, Nature Clinical Practice Neurology.

[74]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  J. Izzo,et al.  Targeting the Hedgehog Pathway to Mitigate Treatment Resistance , 2007, Cell cycle.

[76]  T. Strojnik,et al.  Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. , 2007, Surgical neurology.

[77]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[78]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[79]  S. Rutella,et al.  Expression of CD133-1 and CD133-2 in ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[80]  S. Phuphanich,et al.  A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401) , 2007 .

[81]  Bengt Widegren,et al.  Glioma stem cells: evidence and limitation. , 2007, Seminars in cancer biology.

[82]  Li Zhang,et al.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  B. Ang,et al.  Insights into the cancer stem cell model of glioma tumorigenesis. , 2007, Annals of the Academy of Medicine, Singapore.

[84]  D. Hicklin,et al.  Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. , 2007, Cancer research.

[85]  Caterina A M La Porta,et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. , 2007, European journal of cancer.

[86]  T. Cloughesy,et al.  PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors , 2007, Clinical Cancer Research.

[87]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[88]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[89]  E. Holland,et al.  Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. , 2007, Neurosurgery clinics of North America.

[90]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[91]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[92]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[93]  Takahiro Kunisada,et al.  Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. , 2006, Biochemical and biophysical research communications.

[94]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[95]  Ian F. Pollack,et al.  Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells , 2006, Journal of Pharmacology and Experimental Therapeutics.

[96]  Mark Noble,et al.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo , 2006, Journal of biology.

[97]  P. Włodarski,et al.  Activation of Akt and Erk pathways in medulloblastoma. , 2006, Folia neuropathologica.

[98]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[99]  S. Vandenberg,et al.  PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.

[100]  D. Gutmann,et al.  The neurobiology of neurooncology , 2006, Annals of neurology.

[101]  Angelo L. Vescovi,et al.  Brain tumour stem cells , 2006, Nature Reviews Cancer.

[102]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[103]  A. Unterberg,et al.  Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. , 2006, Cancer treatment reviews.

[104]  H. Li,et al.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.

[105]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  A. Levitzki,et al.  EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice , 2005, PLoS medicine.

[107]  R. Samulski,et al.  Adeno-associated virus vectors: potential applications for cancer gene therapy , 2005, Cancer Gene Therapy.

[108]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[109]  R. McLendon,et al.  ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors , 2005, Clinical Cancer Research.

[110]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[111]  Susan M. Chang,et al.  Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 , 2005, Clinical Cancer Research.

[112]  G. Reifenberger,et al.  Genetic alteration and expression of the phosphoinositol‐3‐kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas , 2005, Neuropathology and applied neurobiology.

[113]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[114]  K. Ichimura,et al.  Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas , 2005, Journal of Molecular Medicine.

[115]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[116]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[118]  K. Hoang-Xuan,et al.  EGFR tyrosine kinase domain mutations in human gliomas , 2005, Neurology.

[119]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[121]  Jing Lin,et al.  Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. , 2005, Cancer research.

[122]  T. Yoshimine,et al.  Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion , 2005, Journal of Clinical Pathology.

[123]  Alan Carleton,et al.  Sonic hedgehog controls stem cell behavior in the postnatal and adult brain , 2005, Development.

[124]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[125]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[126]  Joel I. Pritchard,et al.  The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas , 2004, Cancer Research.

[127]  P. Dirks,et al.  Cancer stem cells in nervous system tumors , 2004, Oncogene.

[128]  E. Holland.  Mouse models of human cancer as tools in drug development. , 2004, Cancer cell.

[129]  D. Wion,et al.  Development of gliomas: potential role of asymmetrical cell division of neural stem cells. , 2004, The Lancet. Oncology.

[130]  Martin Bendszus,et al.  PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. , 2004, Neurosurgery.

[131]  J. Provenzale,et al.  A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[133]  Caterina Giannini,et al.  Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.

[134]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[135]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[136]  H. Newton.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis , 2004, Expert review of anticancer therapy.

[137]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Gregory Y. Lauwers,et al.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.

[139]  Yutaka Shimada,et al.  Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours , 2003, Nature.

[140]  H. Newton.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways , 2003, Expert review of anticancer therapy.

[141]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[142]  Andrew P. McMahon,et al.  Sonic Hedgehog Is Required for Progenitor Cell Maintenance in Telencephalic Stem Cell Niches , 2003, Neuron.

[143]  H. Hanafusa,et al.  PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1 , 2003, Molecular and Cellular Biology.

[144]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[145]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[146]  R. Jenkins,et al.  Recent advances in the molecular genetics of primary gliomas , 2003, Current opinion in oncology.

[147]  C. James,et al.  Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. , 2003, Frontiers in bioscience : a journal and virtual library.

[148]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[149]  Paul S Mischel,et al.  Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.

[150]  G. Konopka,et al.  Signaling pathways regulating gliomagenesis. , 2003, Current molecular medicine.

[151]  S. Datta,et al.  Drosophila perlecan modulates FGF and hedgehog signals to activate neural stem cell division. , 2003, Developmental biology.

[152]  J. Nalbantoglu,et al.  Gene Therapy with Virus Vectors for specific Disease of the Nervous System: The Principles Of Molecular Therapies For Glioblastoma , 2003 .

[153]  F. Gage,et al.  Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo , 2003, Nature Neuroscience.

[154]  Allan H Friedman,et al.  Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[155]  M. Israel,et al.  Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.

[156]  B. Druker,et al.  Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.

[157]  M. Bhatia.  AC133 expression in human stem cells , 2001, Leukemia.

[158]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[159]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[160]  D. Steindler,et al.  Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[161]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[162]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[163]  M. Mehler,et al.  Developmental changes in neural progenitor cell lineage commitment do not depend on epidermal growth factor receptor signaling , 2000, Journal of neuroscience research.

[164]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  D. Bigner,et al.  Molecular pathogenesis of malignant gliomas. , 1999, Current opinion in oncology.

[166]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[167]  A. Baron-Van Evercooren,et al.  Developmental Expression of Platelet-Derived Growth Factor α-Receptor in Neurons and Glial Cells of the Mouse CNS , 1997, The Journal of Neuroscience.

[168]  T. Ohnishi,et al.  Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. , 1996, Cancer research.

[169]  P. Black,et al.  Microvessel density is a prognostic indicator for patients with astroglial brain tumors , 1996, Cancer.

[170]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[171]  W. Snider,et al.  Developmental expression of the platelet-derived growth factor alpha-receptor gene in mammalian central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[172]  Collins Vp.  Amplified genes in human gliomas. , 1993 .

[173]  U. Lendahl,et al.  Expression of the class VI intermediate filament nestin in human central nervous system tumors. , 1992, Cancer research.

[174]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[175]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[176]  M. Loeffler,et al.  Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. , 1990, Development.

[177]  M. Waterfield,et al.  Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor ceil , 1988, Nature.